{"title":"Metabolic Disorder Perturb Renal Homeostasis","authors":"I. Sharma, Y. Liao, X. Zheng, Kanwar Ys","doi":"10.26420/AUSTINJNUTRIFOODSCI.2021.1151","DOIUrl":null,"url":null,"abstract":"Obesity related nephropathy disorders have increased ten-folds in recent years. One of the consequences of obesity is an increased Glomerular Filtration Rate (GFR) that leads to an enlargement of the renal glomerulus, i.e., glomerulomegaly. This heightened hyper-filtration in the setting of type 2 diabetes irreparably damages the kidney and leads to the progression of an End Stage Renal Disease (ESRD). Patients suffering from type 2 diabetes have progressive proteinuria, and eventually one third of them develop Chronic Kidney Disease (CKD) and ESRD. For ameliorating the progression of CKD inhibitors of Renin Angiotensin Aldosterone System (RAAS) seemed to be effective, but for short-term basis only. Long term and stable treatment strategies like weight loss via restricted or hypo-caloric diet or bariatric surgery have yielded more promising results in terms of proteinuria and maintenance of GFR. Body Mass Index (BMI) is considered as a traditional marker for obesity onset, but apparently, it is not a reliable indicator, and thus there is a need for more precise evaluation of regional fat distribution and amount of muscle mass. With respect to the pathogenesis, recent investigations have suggested perturbation in fatty acid and cholesterol metabolism as the critical mediators in ectopic renal lipid accumulation, inflammation, increased generation of ROS, RAAS activation and consequential tubulo-interstitial fibrosis. This review summarizes the renewed approaches for obesity assessment and evaluation of the pathogenesis of CKD, altered renal hemodynamics and potential therapeutic targets.","PeriodicalId":16764,"journal":{"name":"Journal of Nutrition and Food Sciences","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutrition and Food Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/AUSTINJNUTRIFOODSCI.2021.1151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Obesity related nephropathy disorders have increased ten-folds in recent years. One of the consequences of obesity is an increased Glomerular Filtration Rate (GFR) that leads to an enlargement of the renal glomerulus, i.e., glomerulomegaly. This heightened hyper-filtration in the setting of type 2 diabetes irreparably damages the kidney and leads to the progression of an End Stage Renal Disease (ESRD). Patients suffering from type 2 diabetes have progressive proteinuria, and eventually one third of them develop Chronic Kidney Disease (CKD) and ESRD. For ameliorating the progression of CKD inhibitors of Renin Angiotensin Aldosterone System (RAAS) seemed to be effective, but for short-term basis only. Long term and stable treatment strategies like weight loss via restricted or hypo-caloric diet or bariatric surgery have yielded more promising results in terms of proteinuria and maintenance of GFR. Body Mass Index (BMI) is considered as a traditional marker for obesity onset, but apparently, it is not a reliable indicator, and thus there is a need for more precise evaluation of regional fat distribution and amount of muscle mass. With respect to the pathogenesis, recent investigations have suggested perturbation in fatty acid and cholesterol metabolism as the critical mediators in ectopic renal lipid accumulation, inflammation, increased generation of ROS, RAAS activation and consequential tubulo-interstitial fibrosis. This review summarizes the renewed approaches for obesity assessment and evaluation of the pathogenesis of CKD, altered renal hemodynamics and potential therapeutic targets.
近年来,与肥胖相关的肾病增加了10倍。肥胖的后果之一是肾小球滤过率(GFR)增加,导致肾小球增大,即肾小球肿大。在2型糖尿病患者中,这种升高的超滤会对肾脏造成不可修复的损害,并导致终末期肾病(ESRD)的进展。2型糖尿病患者有进行性蛋白尿,最终三分之一的患者发展为慢性肾脏疾病(CKD)和ESRD。为了改善CKD的进展,肾素血管紧张素醛固酮系统抑制剂(RAAS)似乎是有效的,但只是短期的基础。长期稳定的治疗策略,如通过限制或低热量饮食或减肥手术减肥,在蛋白尿和维持GFR方面产生了更有希望的结果。体重指数(Body Mass Index, BMI)被认为是肥胖发病的传统标志,但显然,它不是一个可靠的指标,因此需要更精确地评估区域脂肪分布和肌肉量。关于发病机制,最近的研究表明,脂肪酸和胆固醇代谢的紊乱是异位肾脂质积累、炎症、ROS生成增加、RAAS激活和随之而来的小管间质纤维化的关键介质。本文综述了肥胖评估和CKD发病机制、肾脏血流动力学改变和潜在治疗靶点的新方法。